Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VEX versus weekly paclitaxel in ER-positive/HER2-negative advanced or metastatic breast cancer
2016-002200-39Phase 2Terminated
- Sponsor
- International Breast Cancer Study Group
- Start
- Jan 2018
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of vinorelbine, cyclophosphamide, capecitabine and paclitaxel in breast cancer (2 arms), sponsored by International Breast Cancer Study Group. Primary endpoint: Time to treatment failure. Started Jan 2018; status: terminated.
02
Drugs
vinorelbinecyclophosphamidecapecitabinepaclitaxel
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2016-002200-39.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-002200-39.